Boehringer Ingelheim Pharmaceuticals, Inc. announced today that STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray is now available by prescription at pharmacies across the United States.
In May 2015, the U.S. Food and Drug Administration (FDA) approved STIOLTO RESPIMAT for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). STIOLTO RESPIMAT is not indicated to treat asthma or acute deterioration of COPD.
"For more than 40 years, Boehringer Ingelheim has been an industry leader in the discovery and development of new treatment options for the COPD community. In fact, we began our scientific research of COPD when there were no available options, and now offer six therapies for people living with this chronic disease," said Kathleen M. Dowd, senior vice president, Marketing, Boehringer Ingelheim Pharmaceuticals, Inc. "We are proud to offer patients STIOLTO RESPIMAT, which has proven to be more effective in improving lung function than either tiotropium or olodaterol alone, with a comparable safety profile."
Boehringer Ingelheim Pharmaceuticals, Inc.